Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
To establish in vivo model of anemia, we established and crossed 1) GATA-1 promoter (G1HRD)/reverse tetracycline transactivator (rtTA)-transgenic mice and 2) Tetracycline-responsive element (TRE)/Lmo2 shRNA-tranegenic mice. In the established mice (Tg-TRE-Lmo2 shRNA::Tg-G1HRD-rtTA), Lmo2 shRNA is expected to be induced specifically in erythroblasts by tetracycline administration, leading to the onset of anemia. Our established system would be applied to establish wide variety of in vivo anemia models by targeting to erythroid genes other than Lmo2.
|